Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Choline chloride is a salt of choline, an essential nutrient that serves as a precursor for the neurotransmitter acetylcholine and membrane phospholipids such as phosphatidylcholine. It is being developed primarily as an intravenous (IV) supplement for patients with intestinal failure who are receiving long-term parenteral nutrition (PN). Because standard PN formulations often lack choline, these patients frequently develop choline deficiency, which can lead to Intestinal Failure-Associated Liver Disease (IFALD), characterized by hepatic steatosis and cholestasis. Protara Therapeutics is advancing IV choline chloride (TARA-001) in Phase 2b/3 clinical trials to address this deficiency and mitigate liver damage. Additionally, choline chloride has been investigated for its potential to modulate DNA methylation in Alzheimer's disease models and as a metabolic imaging agent in the form of deuterated choline for tumor detection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline chloride.